Treatment group-specific inferences in Phase III Randomized Oncology Trials.

ABSTRACT:

Background

Estimation of comparative treatment effects between randomized groups is well-supported in randomized trials. By contrast, treatment group-specific inferences are challenging, as patients are selectively chosen for enrollment, and such inferences are formally discouraged by the CONSORT guidelines. The present study is the first-large scale assessment of the proportion of phase III oncology trials that present treatment group-specific inferences.

Methods

Published phase III randomized oncology trials were screened from ClinicalTrials.gov. Treatment group-specific inferences were defined by the presence of 95% CI or standard error for treatment-specific outcomes.

Results

A total of 774 phase III trials enrolling 568,080 patients were included. Treatment group

SUBMITTER: Sherry AD 

PROVIDER: S-EPMC11959831 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature